A New Cancer Treatment Has Given Terminal Patients a Second Chance at Life

一種新的癌症療法給予末期病人第二次生命機會

IN BRIEF

   •     Gene therapy has been shown in clinical trials to not just treat cancer, but possibly cure it.

   •     The treatments have risks — including death — so additional research is needed before they could become widely available.

 

摘要

 

在臨床試驗中,基因治療不只能緩解癌症,甚至可能完全治癒癌症。

 

這種治療有它的風險,包括死亡的風險,所以在這種療法普及之前,我們還有進一步的研究要進行。

 

COULD THIS TREATMENT CURE CANCER?

這種療法能完全治癒癌症嗎?

Despite the many advances in medicine over the last century, a cure for one of the most prevalent and devastating diseases in the world today continues to evade us. But thanks to new research, that could soon change.

Kite Pharma, a US pharmaceutical company, just released the groundbreaking resultsof their six-month gene therapy trial: terminal cancer patients in complete remission after just a single round.

 

雖然我們的醫學在上個世紀中進步很多,但是對於今日世界上最普遍、最具破壞性的疾病,卻還沒有研發出真正的解藥。但是,感謝新研究的出現,這種情形很快就會改變。Kite Pharma風箏製藥)是一家美國製藥公司,它剛剛發表極具突破性的研究結果,這個研究是為期半年的基因治療臨床試驗:癌症末期病人的病況在單單一輪試驗後就完全緩解。

 

The treatment filters a patient’s blood to remove T-cells無連結, immune system cells that can be genetically engineered in a lab to identify cancer cells. Cancer cells thrive because of their ability to evade the immune system. This new therapy boosts immune cells so that they are able to eliminate cancer cells more effectively.

 

這種療法是將病人的血液過濾,以此移除T細胞,免疫系統細胞可以在實驗室中被基因改造,使細胞能分辨癌細胞。癌細胞會興起是因為它們能躲避免疫系統。這種新療法可以讓免疫細胞提升,所以免疫細胞能更有效地消除癌細胞。

 

Patients who participated in the trial had one of three types of non-Hodgkin lymphoma. The advanced stage of their conditions meant all of them were given only a few months to live. However, following the first round of gene therapy, which took place nine months after the trial began, half the patients are not only still alive, but a third of them appear to be cured.

Among them is a 43- year-old named Dimas Padilla from Orlando, Florida whose cancer had stopped responding to chemotherapy. He completed the first round of the trial’s treatment last August, and his cancer is now in remission.

 

參加這個試驗的病人所得的是三種癌當中的非何傑金氏淋巴癌non-Hodgkin lymphoma  )。這些病人的病況如果再惡化,他們剩下的時間就會只有短短數月了。然而,在第一輪基因治療後、試驗開始後第九個月時,有一半的受試病人還活著,而且在他們之中有三分之一的人似乎被完全治癒。被治癒的人中,有一位四十三歲的病人名叫 Dimas Padilla,他來自佛羅里達州奧蘭多。在接受試驗之前,化療已對他的癌症失去效用。在上個八月份,他完成第一輪試驗,而且他的癌症現在已經緩解。

 

WORTH THE RISK?

值得冒險嗎?

These results are promising and suggest that one day CAR-T cells could become a treatment option for some patients with certain types of lymphoma,” said head cancer information nurse, Martin Ledwick from the Cancer Research UK, in an interview with The Telegraph.

While the results are promising and could prove to be life- changing for patients with terminal cancer, the treatment is not without risks.

 

 

來自英國癌症研究中心Cancer Research UK)的首席癌症資訊護士Martin Ledwick在一次與The Telegraph的訪談中表示:「這些結果帶來了希望,將來有一天嵌合抗原受T 细胞免疫CAR-T cells)可以成為特定淋巴癌患者的治療選項之一。」

 

雖然試驗結果帶來希望,並且可以為正在化療的癌症患者帶來極大的人生改變,但這種療法還是有風險的。

 

Because the therapy essentially puts the human immune system to go into overdrive by radically altering human cells, complications are certainly possible — some of which could be fatal. In fact, during the trial, two people died as a result of the therapy — not because of the cancer. Some patient’s immune systems overreacted in its effort to kill the cancer cells, while others developed blood-count related issues such as anemia無連結. Reports of patients suffering from neurological problems were also cited, but these side effects apparently only lasted a few days.

 

因為這種療法實際上是從根本上改變人類細胞,以此讓人類免疫系統超速運轉,如此一來,極有可能引發併發症,而有些併發症會致命。事實上,在試驗期間,有兩位病人在接受試驗後離世,但不是因為癌症。有些病人的免疫系統在消滅癌細胞時運作過度,有些病人的血象則有貧血症的問題。另外,也有記錄顯示有病人因神經問題而痛苦,但以上副作用很明顯只有持續幾天。

 

More studies are needed to understand the therapy’s side effects, potential complications, and long-term benefits.

The trial’s full results won’t be presented until April, and the pharmaceutical company still has to get approval from the European regulatory boards — which means it will be a while yet before the therapy becomes available. Given the possible risks, it might give them enough time to study the therapy further and refine the process — hopefully eliminating any adverse effects.

Although, as the Cancer Institute’s Dr. Steven Rosenberg points out: It’s a safe treatment, certainly a lot safer than having progressive lymphoma.”

 

我們需要更多的研究來理解這種療法的副作用、潛在併發症、長期效益。

 

這個試驗的全部結果要等到四月份才公布,製藥公司也必須得到歐洲管制委員會的許可,也就是說這種療法還要一陣子才能被使用。可能的風險是存在的,前述原因讓能研究人員有足夠的時間來更進一步研究這種療法,並且完善過程。希望能消除所有副作用。

 

雖然,如癌症研究所的Steven Rosenberg博士所說:「這是一種安全的療法,絕對比漸進性淋巴癌安全得多。」

 

 

「語音合成由賽微科技提供」

 

來源:futurism